Ruggie Capital Group’s Myriad Genetics MYGN Stock Holding History

Ruggie Capital Group’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-100	Closed	-$3K	–	343
2018 Q4	$3K	Buy	+100	New	+$3.6K	﹤0.01%	415

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Ruggie Capital Group's MYGN Position: Q1 2019 in Review

Ruggie Capital Group sold out of Myriad Genetics (MYGN) in Q1 2019, closing a stake of 100 shares — an estimated $3K sold.

Ruggie Capital Group first reported a position in MYGN in Q4 2018 and held it in 1 quarter. The position peaked at $3K in Q4 2018. 262 funds tracked by Wall St. Rank hold MYGN as of Q1 2019.

Ruggie Capital Group reported no remaining Myriad Genetics position as of Q1 2019 after selling out during the quarter.
Ruggie Capital Group sold 100 Myriad Genetics shares in Q1 2019, an estimated $3K.
Ruggie Capital Group first reported a position in Myriad Genetics in Q4 2018 and held it in 1 quarter.
Ruggie Capital Group's Myriad Genetics position peaked at $3K in Q4 2018.
262 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2019.

Based on Ruggie Capital Group's 13F filing for Q1 2019, filed 24 Apr 2019.